Dr. Hong on High-Dose Hypofractionated Proton Beam Therapy for Liver Cancer

Video

Theodore S. Hong, MD, director, Gastrointestinal Service, Department of Radiation Oncology, discusses high-dose hypofractionated proton beam therapy for unresectable primary liver cancers.

Theodore S. Hong, MD, director, Gastrointestinal Service, Department of Radiation Oncology, discusses high-dose hypofractionated proton beam therapy for unresectable primary liver cancers.

Numerous liver-directed therapies have emerged for patients with unresectable liver cancer, and among those, radiation therapy has shown promising results in ablating tumors that may exceed the size criteria for other, more invasive techniques.

Unlike conventional X-rays used in stereotactic radiation therapy, Hong says protons allow for a higher dose of radiation to be administered to a liver tumor while still protecting the normal liver.

Hong adds that this therapy is especially important for primary liver cancers because many patients have significant underlying liver dysfunctions, such as hepatitis C, hepatitis B, or alcoholic cirrhosis.

<<<

View more from the 2016 GI Cancer Symposium

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center